Open access · CC-BY
via OpenAlex
Alpha-Synuclein Aggregation Pathway in Parkinson’s Disease: Current Status and Novel Therapeutic Approaches
Marija Vidović, Milena Rikalović
Cells · 2022 · ▲ 199 citations
Abstract
Following Alzheimer's, Parkinson's disease (PD) is the second-most common neurodegenerative disorder, sharing an unclear pathophysiology, a multifactorial profile, and massive social costs worldwide. Despite this, no disease-modifying therapy is available. PD is tightly associated with α-synuclein (α-Syn) deposits, which become organised into insoluble, amyloid fibrils. As a typical intrinsically disordered protein, α-Syn adopts a monomeric, random coil conformation in an aqueous solution, while its interaction with lipid membranes drives the transition of the molecule part into an α-helical structure. The central unstructured region of α-Syn is involved in fibril formation by converting to well-defined, β-sheet rich secondary structures. Presently, most therapeutic strategies against PD are focused on designing small molecules, peptides, and peptidomimetics that can directly target α-Syn and its aggregation pathway. Other approaches include gene silencing, cell transplantation, stimulation of intracellular clearance with autophagy(definition) promoters, and degradation pathways based on immunotherapy of amyloid fibrils. In the present review, we sum marise the current advances related to α-Syn aggregation/neurotoxicity. These findings present a valuable arsenal for the further development of efficient, nontoxic, and non-invasive therapeutic protocols for disease-modifying therapy that tackles disease onset and progression in the future.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/cells11111732
- Canonical
- link ↗
- Fetched
- 2026-10-03 MST
Cite this
APA
Vidović, M., & Rikalović, M. (2022). Alpha-Synuclein Aggregation Pathway in Parkinson’s Disease: Current Status and Novel Therapeutic Approaches. <em>Cells</em>. https://doi.org/10.3390/cells11111732
Vancouver
Vidović M, Rikalović M. Alpha-Synuclein Aggregation Pathway in Parkinson’s Disease: Current Status and Novel Therapeutic Approaches. Cells. 2022. doi:10.3390/cells11111732.
BibTeX
@article{marija2022AlphaS,
title = {Alpha-Synuclein Aggregation Pathway in Parkinson’s Disease: Current Status and Novel Therapeutic Approaches},
author = {Marija Vidović and Milena Rikalović},
journal = {Cells},
year = {2022},
doi = {10.3390/cells11111732},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of Neurochemistry 2016
Preprint · OA
The amyloid cascade hypothesis: are we poised for success or failure?
Neurobiology of Disease 2024
Open access · CC-BY
Interactions of alpha-synuclein with membranes in Parkinson's disease: Mechanisms and therapeutic strategies
Proceedings of the National Academy of Sciences 2016
Open access · OA
Mutations associated with familial Parkinson’s disease alter the initiation and amplification steps of α-synuclein aggregation
Cellular and Molecular Neurobiology 2025
Open access · CC-BY
Alpha-Synuclein Pathophysiology in Neurodegenerative Disorders: A Review Focusing on Molecular Mechanisms and Treatment Advances in Parkinson’s Disease
Frontiers in Aging Neuroscience 2018
Open access · CC-BY
Recent Advances: Decoding Alzheimer’s Disease With Stem Cells
Annals of Clinical and Translational Neurology 2014
Open access · CC-BY